We are analyzing https://link.springer.com/article/10.1186/1475-2840-4-13.

Title:
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] | Cardiovascular Diabetology
Description:
Objective The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

study, diabetes, patients, article, google, scholar, disease, cholesterol, fenofibrate, trial, cardiovascular, field, risk, heart, coronary, pubmed, cas, type, treatment, randomized, effects, years, therapy, mellitus, events, intervention, trials, placebo, hdl, australia, table, data, event, baseline, investigators, runin, lipid, fibrate, randomization, cohort, prevention, research, lowering, access, chd, metabolic, triglycerides, participants, outcomes, zealand,

Topics {✒️}

open access article double-blind placebo-controlled study hmg-coa reductase inhibitors peroxisome proliferator-activated receptor raising high-density lipoprotein heart protection study article download pdf medical research council low-density lipoprotein cholesterol single-blind placebo run va-hit study group randomised placebo-controlled trial ukpds risk engine heart failure related long-term fibrate therapy matching long-term placebo coronary heart disease ppar-alpha agonist action community-based subjects chose open-cholesterol treatment full access flinders medical centre national heart foundation high-density lipoprotein low-density lipoprotein privacy choices/manage cookies generate clinical information parallel-group trial lipid study group 6-week active-treatment run receiving matching placebo impaired fasting glucose established coronary atherosclerosis lipid-modifying trials laboratoires fournier sa placebo-controlled trial coronary artery disease helsinki heart study placebo-controlled study long-term intervention including low hdl high waist measurement field study investigators cardiovascular benefits high cardiovascular risk local ethics committees atp iii criteria high risk status placebo-treated group lipid-modifying therapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
         description:The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005.
         datePublished:2005-08-22T00:00:00Z
         dateModified:2005-08-22T00:00:00Z
         pageStart:1
         pageEnd:9
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1475-2840-4-13
         keywords:
            Fenofibrate
            Coronary Heart Disease Event
            Heart Protection Study
            Fibrate Therapy
            UKPDS Risk Engine
            Diabetes
            Angiology
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2840-4-13/MediaObjects/12933_2005_Article_47_Fig1_HTML.jpg
         isPartOf:
            name:Cardiovascular Diabetology
            issn:
               1475-2840
            volumeNumber:4
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
      description:The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005.
      datePublished:2005-08-22T00:00:00Z
      dateModified:2005-08-22T00:00:00Z
      pageStart:1
      pageEnd:9
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1475-2840-4-13
      keywords:
         Fenofibrate
         Coronary Heart Disease Event
         Heart Protection Study
         Fibrate Therapy
         UKPDS Risk Engine
         Diabetes
         Angiology
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1475-2840-4-13/MediaObjects/12933_2005_Article_47_Fig1_HTML.jpg
      isPartOf:
         name:Cardiovascular Diabetology
         issn:
            1475-2840
         volumeNumber:4
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cardiovascular Diabetology
      issn:
         1475-2840
      volumeNumber:4
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png

External Links {🔗}(102)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.09s.

LINK . SPRINGER . COM {}